Absstract of: US2023081837A1

In alternative embodiments, provided are pharmaceutical compositions comprising combinations of drugs, including products of manufacture and kits, and methods for using them, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a coronavirus infection, or a COVID-19 or a 2019-nCoV (or so-called Wuhan coronavirus) infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, combinations, or cocktails, of a drug or drugs as provided herein are administered either enterally, parenterally and/or by inhalation. In alternative embodiments, combinations, or cocktails, of drugs as provided herein are used to block intracellular metabolic pathways and prevent progression of the infection to clinical illness and death. In alternative embodiments, novel aerosol, spray or mist or powder formulations for inhalation are provided. In alternative embodiments, provided are therapeutic combinations of drugs or a drug, a pharmaceutical dosage form, a drug delivery device, or a product of manufacture, comprising: opaganib or YELIVA™, or opaganib or YELIVA™ and oral and/or inhaled chloroquine (or ARALEN™) chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (optionally, PLAQUENIL™), with or without azithromycin, wherein optionally each or all of the opaganib, the chloroquine (or ARALEN™), ch

Absstract of: US2023084300A1

The present invention relates to the use of an immunomodulator comprising non-pathogenic non-viable Mycobacterium, such as Mycobacterium obuense (IMM-101), and one or more biologically-active agents, suitably an antigen or antigenic determinant, in a method of treating or preventing a infection and/or the symptoms associated thereof in a human subject at elevated risk of exposure to and/or severity of said infection, such as a healthcare or social care worker or cancer patient, wherein said viral infections are preferably caused by a coronavirus. The invention is particularly applicable to those infections caused by SARS-CoV, MERS-CoV, or SARS-CoV-2 (COVID-19). The invention also provides an adjuvant and pharmaceutical composition comprising said immunomodulator optionally with a pharmaceutically acceptable carrier, diluent or excipient, as well as the use of said adjuvant or said pharmaceutical composition in the manufacture of a medicament for the treatment or preventions of said infections.

Absstract of: US2023084035A1

Provided herein are methods for reducing risk of severe symptoms and outcomes associated with Coronavirus Disease 2019 (COVID-19) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection by measuring levels of interleukin 6 (IL-6), IL-8, IL-22, and serum ferritin in a subject. Also provided are methods for treating a subject exposed to or at elevated risk of expose to SARS-CoV-2 based on levels of IL-6, IL-8, IL-22, and ferritin in the serum of the subject.

Absstract of: US2023085607A1

Disclosed are novel mechanisms of action of ivermectin therapy as related to treatment of COVID-19 and means of augmenting therapeutic activities by co-administration with one or more of the following: pterostilbene, thymoquinone, epigallocatechin-3-gallate, and sulforaphane. In one embodiment the invention provides enhanced reduction of inflammation induced pulmonary leakage without augmenting immune suppressive mechanisms.

Absstract of: US2023082992A1

The invention provides the use of a formulation containing cyclodextrine, quercetin and zinc, at appropriate concentrations to mitigate infections by enveloped viruses like SARS-CoV-2, influenza and HIV/AIDS, when administered via pulmonary and dermal route. While the different forms of cyclodextrin prevent the entry of coated virus into host cells by extracting and sequestering cholesterol molecules at the virus coat and at the host cell plasma membrane, the natural plant-based ionophore quercetin in the formulation, enables cellular entry of zinc, inhibiting viral replication by altering polymerase activity in the host cell. Hence cyclodextrine, and quercetin plus zinc, either in combination or in tandem order of administration, serves both as prophylactic and therapeutic.

Absstract of: US2023080265A1

The present disclosure relates to genetically modified non-human animals (e.g., genetically-modified mice or rodents) that express a hACE2 and/or hTMPRRS2 under control of the mouse promoter and the genetically modified non-human animal does not express native ACE2 and/or hTMPRRS2. The present disclosure also relates to methods of generating the genetically-modified animals (e.g., genetically modified mice or rodents), and methods of using the genetically modified non-human animals (e.g., genetically modified mice or rodents) described herein.

Absstract of: WO2023039108A1

Compositions and methods for the prevention and/or treatment of SARS-CoV-2 infection and/or COVID-19 are described.

Absstract of: WO2023039442A1

The present disclosure provides antibody combinations and related methods for treating a SARS-CoV-2 infection in a subject or for manufacturing a medicament for the treatment of a SARS-CoV-2 infection. In some aspects, therapy comprises two antibodies that bind compete for binding to a SARS-CoV-2 surface (S) glycoprotein monomer. The antibody combinations can potently neutralize SARS-CoV-2, can broadly neutralize SARS-CoV-2 variants, and are resistant to viral breakthrough. Antibody compositions comprising such combinations are also provided.

Absstract of: WO2023039474A1

Disclosed herein are cross-linked peptides either alone or conjugated to PEG(n)-cholesterol (or thiocholesterol) moieties useful for interfering with and inhibiting or preventing coronavirus infection (e.g., infection by SARS-CoV-2). Also disclosed are methods of treating and/or preventing a coronavirus infection (e.g., COVID-19.

Absstract of: WO2023036982A1

The invention relates to antibodies that recognize SARS-CoV-2 spike protein (SARS2-S). In some embodiments, the antibodies bind to SARS2-S with high affinity and potently neutralize a broad range of SARS-CoV-2 variants of concern. In some embodiments, the antibodies provide a means of preventing, treating or ameliorating SARS2 infection. In some embodiments, the antibodies are used in diagnostic assays (e.g. serodiagnostic assays for SARS2).

Absstract of: WO2023036986A2

The invention relates to heavy chain-only antibodies that recognize SARS-CoV-2 spike protein (SARS2-S). In some embodiments, the antibodies bind to SARS2-S with high affinity and/or inhibit SARS-Cov-2 infection of human cells. In some embodiments, the antibodies provide a means of preventing, treating or ameliorating SARS2 infection. In some embodiments, the antibodies are used in diagnostic assays (e.g. serodiagnostic assays for SARS2).

Absstract of: WO2023037387A2

: FREEZE-DRIED VIRAL COMBINATION VACCINE COMPOSITIONS AND PROCESS FOR PREPARATION THEREOF The present disclosure relates to field of lyophilized/freeze-dried viral combination composition/formulation and methods for manufacturing and obtaining the composition comprising at least three live attenuated virus selected from a group of Coronavirus, Measles virus and Rubella virus; and stabilizers comprising of at least one carbohydrate, at least one amino acid and at least one hydrolyzed protein. The said lyophilized/freeze-dried viral combination composition/formulation is a vaccine composition that preserves the desired characteristics of each virus, including stability and immunogenicity. The composition can be safely administered subcutaneously as a combination vaccine composition such that the immunogenicity of each of the measles, rubella and SARS-CoV-2 is not inferior to that observed for each of the three viruses when administered as individual vaccines and is found to be equivalent or improved as compared to immunogenicity of SARS-CoV-2 vaccine given intranasally. The purification process is devoid of chromatography steps.

Absstract of: WO2023036947A1

The invention relates to a biologically produced nucleic acid sequence comprising two or three primary nucleic acid sequence parts of SARS-CoV-2 and not more than three secondary nucleic acid sequence parts, wherein a secondary nucleic acid sequence part encodes an amino acid sequence having the function of a SARS-CoV-2 amino acid sequence encoded by ORF3a, ORF6, ORF7a or ORF8. The invention further relates to a host cell or a kit for producing the nucleic acid of the invention, a vector encoding the nucleic acid of the invention and products that can be obtained by the expression of the nucleic acid of the invention such as virus envelopes. The invention further relates a pharmaceutical composition comprising the nucleic acid of the invention or products derived thereof, preferably for use in the prevention of SARS-CoV-2.

Absstract of: WO2023036871A1

The invention relates to an RNA for inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication. According to an aspect of the invention, the RNA is an at least partially double-stranded RNA having a sequence being at least 95 % identical to a sequence chosen from the group consisting of SEQ ID NO. 6 and SEQ ID NO. 11.

Absstract of: US2023082940A1

The invention discloses a biosensor device (100) to detect the presence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in a biological sample. The device includes an optical fiber probe (104) having a curved portion (104a) with a probe region (105) immobilized with bioreceptor molecules (201) configured to bind to the target molecule V indicative of the presence of the SARS-CoV-2. The probe has a light source (102) and a detector (106) on either end. The device works on the principle of plasmonic fiberoptic absorbance biosensing. Plasmonic gold nanoparticles (120) are used as either sensor substrate over the fiber or labels conjugated with a biorecognition molecule (211). The probe is exposed to a biological sample either directly for label-free detection, or after mixing with labels to realize a sandwich assay. The target biomolecules are detected by a proportional drop in the light intensity passing through the probe.

Absstract of: WO2021224606A1

The present invention relates to improved single domain antibodies that target SARS-CoV-2, the use of said single domain antibodies in treating and/or preventing coronavirus, as well as the use of said single domain antibodies in the detection and diagnosis of coronavirus using various methods, assays and kits.

Absstract of: WO2021225767A1

Disclosed herein are methods that are useful for treating a subject who has a pathogenic infection, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); reducing the likelihood of the subject from being infected by a pathogen; and for reducing the transmission of a pathogen from a subject to others. The methods utilize a compound disclosed in Table 1 or Table 4 herein, optionally in combination with an additional agent such as an anti-infective agent.

Absstract of: EP3906919A1

The present invention relates to compounds that are able to inhibt 3CL protease of COVID-19 virus, SARS-Cov-2

Absstract of: WO2021224145A1

The present invention provides methods of treating COVID-19 in a subject using methylthioninium compounds.

Absstract of: WO2021224144A1

The present invention provides methods of treating COVID-19 in a subject using methylthioninium compounds.

Absstract of: EP3906922A1

The present invention relates novel composition to for use in a method of treating COVID-19 comprising administering to a patient a therapeutically effective amount of at least one antagonist or inhibitor of chemokine receptor CXCR4.

Absstract of: WO2021226478A1

One aspect described herein includes a method for treating coronavirus 2019 disease (COVID-19) caused by severe respiratory syndrome coronavirus 2 (SARS-CoV-2) by administering an effective amount of a DHODH inhibitor. Another aspect described herein includes a method of treating COVD-19 by administering 4-chlorophenyl (S)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indole-2-carboxylate (PTC299), or a pharmaceutically acceptable salt thereof.

Absstract of: WO2021226179A2

The invention provides anti-SARS-CoV-2 spike (S) protein antibodies and methods of using the same.

Absstract of: WO2021226111A1

Disclosed are methods for treating neutrophil extracellular trap (NET) mediated inflammatory tissue damage in a patient having COVID-19, comprising administering to the patient having COVID-19 an effective amount of a pharmaceutical composition comprising a NET-inhibitory peptide (NIP) and a pharmaceutically acceptable carrier to reduce a pathological effect or symptom of the NET-mediated inflammatory tissue damage. Disclosed are methods for inhibiting NET formation in a patient having COVID-19 comprising administering to the patient having COVID-19 an effective amount of a pharmaceutical composition comprising a NIP and a pharmaceutically acceptable carrier to substantially inhibit NET formation.

Absstract of: WO2021224918A1

An RNAi molecule, the RNAi molecule, vector and composition including the RNAi molecule and method of using same, wherein the RNAi molecule includes a dsRNA sequence of from about 15 to about 60 base pairs, capable of decreasing expression of a SARS-CoV-2 gene.